<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1120</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2007-3-3-43-45</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыря</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Adjuvant intravesicular chemotherapy for superficial bladder carcinoma</article-title><trans-title-group xml:lang="ru"><trans-title>Адъювантная внутрипузырная химиотерапия поверхностного рака мочевого пузыря</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rusakov</surname><given-names>I. G.</given-names></name><name xml:lang="ru"><surname>Русаков</surname><given-names>И. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bystrov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Быстров</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Teplov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Теплов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Perepechin</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Перепечин</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">P.A. Herzen Moscow Research Oncological Institute</institution></aff><aff><institution xml:lang="ru">Московский научно-исследовательский онкологический институт им. П.А. Герцена</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2007-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2007</year></pub-date><volume>3</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>43</fpage><lpage>45</lpage><history><date date-type="received" iso-8601-date="2020-02-16"><day>16</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-02-16"><day>16</day><month>02</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1120">https://oncourology.abvpress.ru/oncur/article/view/1120</self-uri><abstract xml:lang="en"><p>The paper presents the results of using Vero-Mitomycin in patients with superficial bladder carcinoma (SBC). The study included 23 SBC patients over 18 years of age, with invasion levels of pTa, pT1, and differentiation grades of G1—2, ECOG 0 or 1, who were treated at the Department of Oncourology, P.A. Herzen Moscow Research Oncological Institute. The patients were given 6 intravesicular instillations of Vero-Mitomycin in a single dose of 40 mg. During a follow-up, a recurrence developed in 9 (39.1%) patients, a tumorous process progressed in none patient. There were recurrences at 12—16 months. The acute cystitis syndrome was revealed in 2 patients (after 4 and 6 instillations of the drug). Hematological toxicity was not observed. Thus, Vero-Mitomycin is one of the drugs of choice for the first-line intravesicular chemotherapy in patients with low and moderate risk SBC. Intravesicular chemotherapy with Vero-Mitomycin is an effective and low-toxic preventive method against recurrent SBC.</p></abstract><trans-abstract xml:lang="ru"><p>.</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Soloway M.S., Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer. 1980;46(5):1158—63.</mixed-citation><mixed-citation xml:lang="ru">Soloway M.S., Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer. 1980;46(5):1158—63.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Hirao Y., Okajima E., Ohara S. et al. Prophylactic treatment for superficial bladder cancer following transurethral resection. Cancer Chemother Pharmacol 1987;20 (Suppl):S85—90.</mixed-citation><mixed-citation xml:lang="ru">Hirao Y., Okajima E., Ohara S. et al. Prophylactic treatment for superficial bladder cancer following transurethral resection. Cancer Chemother Pharmacol 1987;20 (Suppl):S85—90.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Elmer A., Bermes U., Drath L. et al. Sepsis and multiple organ failure after BCG-instillation for bladder cancer. Internist (Berl) 2004;45(8):935—9.</mixed-citation><mixed-citation xml:lang="ru">Elmer A., Bermes U., Drath L. et al. Sepsis and multiple organ failure after BCG-instillation for bladder cancer. Internist (Berl) 2004;45(8):935—9.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Carballido J., Molto L.M., Olivier D.P. et al. Analysis of the effect of intravesical treatment with interfero-a-2b on clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors. Anti-Cancer Drugs 1992; 3(Suppl1): 9—12.</mixed-citation><mixed-citation xml:lang="ru">Carballido J., Molto L.M., Olivier D.P. et al. Analysis of the effect of intravesical treatment with interfero-a-2b on clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors. Anti-Cancer Drugs 1992; 3(Suppl1): 9—12.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., Вердана; 2001.</mixed-citation><mixed-citation xml:lang="ru">Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., Вердана; 2001.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Heijden A.G. van der, Witjes J.A. Future strategies in the diagnosis, staging and treatment of bladder cancer. Curr Opin Urol 2003;13(5):389—95.</mixed-citation><mixed-citation xml:lang="ru">Heijden A.G. van der, Witjes J.A. Future strategies in the diagnosis, staging and treatment of bladder cancer. Curr Opin Urol 2003;13(5):389—95.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Shelley M.D., Court J.B., Kynaston H. et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003;(3):CD003231.</mixed-citation><mixed-citation xml:lang="ru">Shelley M.D., Court J.B., Kynaston H. et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003;(3):CD003231.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Soulie M., Straub M., Game X. et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol 2002;167(3):1325—8.</mixed-citation><mixed-citation xml:lang="ru">Soulie M., Straub M., Game X. et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol 2002;167(3):1325—8.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
